Innovative drugs do not enter DRGS, the average reduction of the minimum minimum is the minimum of seven times

1. Benefited by policies, the photovoltaic sector performed brightly on July 14. In terms of news, the Ministry of Housing and Urban -Rural Development issued the "Carbon Peak Implementation Plan for the Field of Urban and Rural Construction", which proposed to optimize the structure of urban construction and promote the integrated solar photovoltaic construction of the building. The plan mentioned in 2025 new public institutions buildings and new factories' top light coverage rates strive to reach 50%.

2. In addition to new energy, the pharmaceutical sector also performed well on July 14. The seventh batch of national organizational drugs were concentrated in Nanjing. In terms of fundamental terms, Guojin Securities stated that the pharmaceutical sector enters the two major windows of the semi -annual report window and summer consumer medical peak. The performance is restored.

On July 14th, the three major indexes divided, and the downturn performance of the blue -chip sectors such as infrastructure and real estate dragged the market performance of the Shanghai Stock Exchange Index. The increase in the sector was the top, and the GEM index rose 2.63%. In terms of individual stocks, the number of stocks rose nearly 2,600, and the number of declines was about 2,000.

In terms of volume, the total turnover of the two cities on July 14 was 1.03 trillion yuan, which was slightly volume compared to yesterday, and returned to the trillion mark. In terms of funds in the north, 917 million yuan was flowed out, of which Shanghai stocks were issued 2.861 billion yuan, and Shenzhen stockflows inflow of 1.944 billion yuan.

Recently, the flow of funds in the north direction, the data comes from Wind

In terms of sectors, the policies were stimulated, and the photovoltaic sector performed brightly on July 14. The increase in the 50ETF (159864) of the photovoltaic 50ETF (159864) once exceeded 4%, as of the closing of 3.60%. On the news, the Ministry of Housing and Urban -Rural Development has recently issued the "Carbon Peak Implementation Plan for the Field of Urban and Rural Construction", which proposes to optimize the structure of urban construction and promote the integrated construction of solar photovoltaic in the building. The plan mentioned in 2025 new public institutions buildings and new plant roof light coverage rates strive to reach 50%, and the solar photovoltaic system is installed with existing public building roofs.

Changjiang Securities stated that since the second half of 2020, carbon peaks, carbon neutrality and policies at home and abroad have been frequently promoted from top to bottom, which has become the degree of certainty and growth of the industry's long -term space; and The economy of the industry is the inherent driving force of the development of the industry.

Facing the era of comprehensive cheap Internet access, the reduction of costs in various links is close to the limit, raw materials and transportation costs have risen, and the industry's demand for high -efficiency battery technology is becoming more urgent. At present, the industrialization of the N -type battery has accelerated, and TOPCON is expected to take the lead in achieving costs and expand production projects densely.

As the cost of photovoltaic systems continued to decline over the past 10 years, compared with coal power relics in some areas, the cost advantage of coal and electricity is further declined with the cost of photovoltaic power generation, and the power of installation demand has grown strongly. In addition, the real potential of photovoltaic has gradually developed, the demand for installation bursts out, and it has bloomed everywhere. In the short -term adjustment, the prospect of the industry does not change the industry. Under the fluctuations of the market, you need to pay attention to dual batch. (For details, please refer to the "technology sector may enter the adjustment period, and the breeding sector may fluctuate with pig prices").

In addition to new energy, the pharmaceutical sector also performed well on July 14. Medical ETF (159828) rose 2.56%, biomedicine ETF (512290) rose 1.97%, and innovative drug Shanghai -Hong Kong -Shenzhen ETF (517110) rose 2.12%.

On July 12, the seventh batch of national organizational drugs were concentrated in Nanjing, and the results of the selection were released. In this collection, 60 drugs were selected and the number of products reached 327. The average decrease of the product was 48%, and the overall decline was milder, which was in line with market expectations. With the continuous deepening of the national collection work, the market has sufficient expectations for collecting mining, and the overall price decline has also stabilized. It is difficult to give high valuations for corporate capital markets that rely on large -category generic drugs to increase profits. Capital reduction and efficiency and innovation transformation will become the main line of the future and long term.

In order to encourage pharmaceutical companies to innovate the transformation, the Beijing Municipal Medical Insurance Bureau issued the "Notice of the Administrative Measures for Payment Management of CHS-DRG New Drug New Technology (Trial)" and decided to carry out 2022 from July 20, 2022 to August 19, 2022 2022 CHS-DRG paid new drug and new technology except for payment declaration.

The except payment management measures issued this time are to further improve the payment related to Beijing's disease diagnosis diagnosis (CHS-DRG). While giving play to the role of CHS-DRG guiding the role of medical behavior, it has stimulated the innovation of new drugs and new technologies, verifying medical insurance for medical insurance Teng cage changing birds, supporting innovative medicine/innovative technology.

In addition, the pharmaceutical sector enters the two major windows of the semi -annual report window period and the summer vacation consumer medical peak. Guojin Securities stated that on the one hand, it attaches great importance to the semi -annual report and the preview of the second quarter. recover.

At the valuation level, after a long market adjustment, the valuation of the pharmaceutical sector is currently at a very low level in history. 2%. Standing at the current point, the further downward space of the subsequent pharmaceutical sector is limited, and the security margin of investment will be relatively high. Later, you can continue to pay attention to related targets such as medical ETF (159828), biomedical ETF (512290), and innovative medicine Shanghai and Hong Kong Shenzhen ETF (517110). (For details, "Medicine: Short -term cautious and optimistic, long -term bottom up"). The rise of new energy and pharmaceutical sectors has also led to the rise of the Science and Technology Entrepreneurship Index. On July 14th, ETF (588360) rose by 2.97%. For friends who want to invest in new energy and pharmaceutical sectors one -click, you can also pay more attention to the ETF (588360) of Science and Technology Entrepreneurship (588360).

risk warning

Investors should fully understand the differences in the method of savings such as funding fixed investment and zero deposit. Regular fixed investment is a simple way to guide investors to make long -term investment and average investment costs. However, regular fixed investment does not avoid the risks inherent in fund investment, cannot guarantee investors to gain benefits, nor is it an equivalent financial management method to replace savings.

Whether it is the stock ETF/LOF/classification fund, it is a variety of securities investment funds with higher expected risks and expected income. Its expected income and expected risk levels are higher than mixed funds, bond funds and currency market funds.

Fund assets invest in science and technology boards and GEM stocks, and will face the unique risks caused by differences in investment targets, market systems, and trading rules. Investors are requested to pay attention.

The short -term rise and fall of the sector/fund is only used as an auxiliary materials for the analysis of the article. It is for reference only and does not constitute a guarantee of fund performance.

In the article, the short -term performance of individual stocks is for reference only, does not constitute stock recommendations, nor does it constitute a prediction and guarantee of fund performance.

The above views are for reference only, and do not constitute investment suggestions or commitments. If you need to buy related fund products, please pay attention to investors' appropriate management regulations, do a good job of risk assessment in advance, and purchase fund products that match it according to your own risk tolerance. The fund has risks, and investment needs to be cautious.

- END -